Rapamycin Reduced Ischemic Brain Damage in Diabetic Animals is Associated with Suppressions of Mtor and ERK1/2 Signaling

Ping Liu,Xiao Yang,Changchun Hei,Yvonne Meli,Jianguo Niu,Tao Sun,P. Andy Li
DOI: https://doi.org/10.7150/ijbs.15624
2016-01-01
International Journal of Biological Sciences
Abstract:The objectives of the present study are to investigate the activation of mTOR and ERK1/2 signaling after cerebral ischemia in diabetic rats and to examine the neuroprotective effects of rapamycin. Ten minutes transient global cerebral ischemia was induced in straptozotocin-induced diabetic hyperglycemic rats and non-diabetic, euglycemic rats. Brain samples were harvested after 16 h of reperfusion. Rapamycin or vehicle was injected 1 month prior to the induction of ischemia. The results showed that diabetes increased ischemic neuronal cell death and associated with elevations of p-P70S6K and Ras/ERK1/2 and suppression of p-AMPKα. Rapamycin ameliorated diabetes-enhanced ischemic brain damage and suppressed phosphorylation of P70S6K and ERK1/2. It is concluded that diabetes activates mTOR and ERK1/2 signaling pathways in rats subjected to transient cerebral ischemia and inhibition of mTOR by rapamycin reduces ischemic brain damage and suppresses the mTOR and ERK1/2 signaling in diabetic settings.
What problem does this paper attempt to address?